References
- Levy AR, Garrison LP Jr. Apples and oranges? Assessing comparative effectiveness and comparative value in the US and other countries. Value Health 13 Suppl 1, S1–S3 (2010).
- Sorenson C, Drummond M, Chalkidou K. Comparative effectiveness research: the experience of the National Institute for Health and Clinical Excellence. J. Clin. Oncol. 30(34), 4267–4274 (2012).
- Levy AR, Mitton C, Johnston KM, Harrigan B, Briggs AH. International comparison of comparative effectiveness research in five jurisdictions: insights for the US. Pharmacoeconomics 28(10), 813–830 (2010).
- Chalkidou K, Tunis S, Lopert R et al. Comparative effectiveness research and evidence-based health policy: experience from four countries. Milbank Q. 87(2), 339–367 (2009).
- Sorenson C. Use of comparative effectiveness research in drug coverage and pricing decisions: a six-country comparison. Issue Brief (Commonw. Fund) 91, 1–14 (2010).
- O’Donnell JC, Pham SV, Pashos CL, Miller DW, Smith MD. Health technology assessment: lessons learned from around the world – an overview. Value Health 12 Suppl 2, S1–S5 (2009).
- Berger ML, Grainger D. Comparative effectiveness research: the view from a pharmaceutical company. Pharmacoeconomics 28(10), 915–922 (2010).
- IMS Consulting Group. AMNOG: Seven Learnings for Strategic Market Access Decisions in Germany. IMS Consulting Group. (2012).
- Mason A, Drummond M, Ramsey S, Campbell J, Raisch D. Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric? J. Clin. Oncol. 28(20), 3234–3238 (2010).
- Turk F. Data generalizability, data transferability, and the political economy of pharmacoeconomic guidelines. Value Health 13(8), 863–864 (2010).
- The American Recovery and Reinvestment Act of 2009, HR1, 111th Congress.
- The Patient Protection and Affordable Care Act of 2010, HR3590, 111th Congress.
- Healthcare Reform Law Section 6301(a), adding section1181(d)(8)(iv) of Title XI of the Social Security Act.
- Vernon JA, Golec JH, Stevens JS. Comparative effectiveness regulations and pharmaceutical innovation. Pharmacoeconomics 28(10), 877–887 (2010).
- Pearson SD, Bach PB. How Medicare could use comparative effectiveness research in deciding on new coverage and reimbursement. Health Aff. (Millwood) 29(10), 1796–1804 (2010).
- Thomas A, Phillips A, Donnelly R, Piech CT. Comparative effectiveness, personalized medicine and innovation: the path forward. Pharmacoeconomics 28(10), 923–930 (2010).
- Mullins CD, Whicher D, Reese ES, Tunis S. Generating evidence for comparative effectiveness research using more pragmatic randomized controlled trials. Pharmacoeconomics 28(10), 969–976 (2010).
- Dentzer S. The researcher-in-chief at the Patient-Centered Outcomes Research Institute. Health Affairs 30(12), 2252–2258 (2011).
- Meltzer DO, Hoomans T, Chung JW, Basu A. Minimal modeling approaches to value of information analysis for health research. Med. Decis. Making 31(6), E1–E22 (2011).
- Meltzer D, Basu A, Conti R. The economics of comparative effectiveness studies: societal and private perspectives and their implications for prioritizing public investments in comparative effectiveness research. Pharmacoeconomics 28(10), 843–853 (2010).
- Hoomans T, Seidenfeld J, Basu A, Meltzer D. Systematizing the Use of Value of Information Analysis in Prioritizing Systematic Reviews (Internet). Agency for Healthcare Research and Quality, MD, USA (2012).
- Meltzer D, Hoomans T, Chung JW, Basu A. Minimal Modeling Approaches to Value of Information Analysis for Health Research [Internet]. Agency for Healthcare Research and Quality, MD, USA (2011).
- Wong W, Ramsey S, Barlow W et al. The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007). Contemp. Clin. Trials 33(6), 1117–23 (2012).
- Woods B, Veenstra D, Hawkins N. Prioritizing pharmacogenetic research: a value of information analysis of CYP2D6 testing to guide breast cancer treatment. Value Health 14(8), 989–1001 (2011).
- Garber AM, Sox HC. The role of costs in comparative effectiveness research. Health Affairs 29(10), 1805–1811 (2010).
- Neumann PJ. Lessons for health technology assessment: it is not only about the evidence. Value Health. 12(Suppl. 2), S45–S48 (2009).
- Greene JA. Swimming upstream: comparative effectiveness research in the US. Pharmacoeconomics 27(12), 979–982 (2009).
- A new value-based approach to the pricing of branded medicines – a consultation. Department of Health, UK (2010).
Websites
- International Network of Agencies for Health Technology Assessment. Global networking for effective healthcare. www.inahta.org/HTA
- Institute of Medicine. Report brief: initial national priorities for comparative effectiveness research [online]. www.iom.edu/cerpriorities
- PCORI – Working Definition of Patient-Centered Outcomes Research (2012). www.pcori.org/what-we-do/pcor/
- American Cancer Society. Cancer Facts & Figures (2010). www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/cancer-facts-and-figures-2010
- Buto K. Comparative effectiveness research and Medicare: Kathy Buto’s view. Health Affairs Blog (2011). http://healthaffairs.org/blog/2011/02/02/comparative-effectiveness-research-and-medicare-kathy-butos-view
- The Institute of Medicine, Committee on Comparative Effectiveness Research Prioritization, Board on Healthcare Services, Initial national priorities for comparative effectiveness research. National Academies Press, Washington, DC, USA (2009). http://books.nap.edu/openbook.php?record_id=12648
- PCORI – National Priorities for Research and Research Agenda (2012). www.pcori.org/assets/PCORI-National-Priorities-and-Research-Agenda-2012-05-21-FINAL.pdf